Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases
Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that the first subject has been dosed in Australia in its Phase 1
Equillium started testing a new medicine on real people in Australia. This is an early step to see if the drug is safe and could help sick patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.